CCR5 and HIV-1 infection: Our results showed that BMS-986158 moderately down-regulated the expression of the CXCR4 and CCR5 co-receptors in the CD4+ T cells (Figure 2D,E), indicating that BMS-986158 does not increase potential de novo HIV-1 infection.